0.29 (-3.00%)
As of Mar 24, 2023
Source:
We are focused on the research and development of medicines which we believe would benefit from improved bio-delivery and/or bio-distribution using our using our proprietary platform drug delivery technologies: Q-Sphera platform: Our disruptive polymer microsphere microtechnology is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. MidaSolve platform: Our innovative oligosaccharide nanotechnology is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. MidaCore platform: Our leading-edge gold nanoparticle, or GNP, nanotechnology is used for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents
Country | United Kingdom |
Headquarters | cardiff |
Phone Number | 44 (0)1235 888300 |
Industry | manufacturing |
CEO | Stephen Stamp |
Website | biodexapharma.com |